Advertisement
Organisation › Details
Pentixapharm Holding AG (FSE Prime Standard: PTP)
Pentixapharm Holding AG was founded in 2024 to incorporate all shares held by Eckert & Ziegler SE in Pentixapharm AG, based in Würzburg, following the spin-off resolved by the Annual General Meetings of Eckert & Ziegler SE and Pentixapharm Holding AG on June 26, 2024. It is intended to list Pentixapharm Holding AG on the Prime Standard of the Frankfurt Stock Exchange. Pentixapharm AG is a clinical-stage radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Pentixapharm’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Clinical studies for both compounds have already commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. Additionally, PentixaFor is being developed as a diagnostic tool for primary aldosteronism (PA), a major cause of hypertension. Pentixapharm is currently preparing a US-centric Phase III registration study with PentixaFor in PA that will start in 2025. *
Start | 2024-10-02 splitoff | |
Group | Pentixapharm (Group) | |
Today | Pentixapharm (Group) | |
Predecessor | Eckert & Ziegler (Group) | |
Industry | RADIOPHARMACEUTICAL (RPT) | |
Industry 2 | diagnostics (medical/biological) | |
Person | Bouterfa, Hakim (Pentixapharm 202410– CEO before Eckert & Ziegler 202306 CMO + OctreoPharm Sciences GmbH) | |
Person 2 | Eckert, Andreas (Eckert & Ziegler) | |
Region | Berlin | |
Country | Germany | |
Street | 10 Robert-Rössle-Str. Campus Berlin-Buch | |
City | 13125 Berlin | |
Tel | +49-30-9489-2600 | |
Address record changed: 2024-09-25 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Pentixapharm Holding AG. (9/23/24). "Press Release: Pentixapharm Holding AG Sets Price Range for Planned IPO [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg. | ||
Record changed: 2024-09-25 |
Advertisement
More documents for Pentixapharm (Group)
- [1] |transkript [Kääb, Georg]. (9/24/24). "First German Life Sciences IPO since 2016 – Radiopharma Company Pentixapharm Lists at Frankfurt Stock Exchange. Interview by |transkript.de/Georg Kääb with Andreas Eckert"....
- [2] Pentixapharm Holding AG. (9/23/24). "Press Release: Pentixapharm Holding AG Sets Price Range for Planned IPO [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg....
- [3] Pentixapharm Holding AG. (9/12/24). "Press Release: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange [Not for US, AU, CA, JP, ZA, et al.]". Berlin & Würzburg....
- [4] Pentixapharm Holding AG. (8/26/24). "Press Release: Pentixapharm AG Receives Orphan Drug Designation for its Radiodiagnostic Tracer PentixaFor in Marginal Zone Lymphoma by the European Medicines Agency". Berlin & Würzburg....
- [5] Pentixapharm AG. (7/3/24). "Press Release: Pentixapharm Acquires Target Discovery Business of Glycotope". Würzburg & Berlin....
- [6] Eckert & Ziegler Strahlen- und Medizintechnik AG. (6/8/23). "Press Release: PentixaPharm Receives BfArM-Clearance for Its Therapeutic to Conduct a Clinical Trial in Lymphoma". Würzburg....
- [7] PentixaPharm GmbH. (2/6/20). "Press Release: PentixaPharm Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics". Würzburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top